New sequences in higher lines of treatment of clear cell carcinoma of the kidney
Prof. MUDr. Jindřich Fínek, Ph.D., MHA
Onkologická a radioterapeutická klinika LF UK a FN, Plzeň
Two new molecules, nivolumab (anti-PD-1) and cabozantinib (a multikinase inhibitor of the VEGF, AXL and MET pathway), are coming into the treatment of metastatic clear cell carcinoma of the kidneys. In the second treatment line, both offer an identical survival extension of five months compared to everolimus. Cabozantinib appears to be more appropriate in patients with bone metastases and when rapid onset of action is required. In contrast, nivolumab has an advantage in patients with high tumor burden.
light cell carcinoma of the kidney, nivolumab, cabozantitib
The full article is only available to subscribers
Become a regular subscriber to our Oncological Review...